Steve Bryson PhD,  —

Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.

Articles by Steve Bryson

Lack of understanding adds to disease burden in AS: Study

People with ankylosing spondylitis (AS) face difficulties in diagnosis and treatment, must deal with the debilitating effects of disease symptoms, and handle adjustments in social roles, often while contending with a lack of understanding and support — all factors that add to an increased disease burden for patients. That’s…

MicroRNAs dysregulated in axSpA, study shows

Certain microRNAs, molecules involved in controlling gene activity, were dysregulated in adults with axial spondyloarthritis (axSpA), a study found. Altered levels of these microRNAs were linked with elevated blood levels of pro-inflammatory signaling proteins implicated in the development and activity of axSpA. MicroRNAs as biomarkers “could help improve the early…

Women with AS at greater risk of pregnancy complications: Study

Women with ankylosing spondylitis (AS) have a greater risk of pregnancy complications that can affect both the mother and the child than do those without the inflammatory condition, a U.S. population-based study found. Among the maternal complications found were higher rates of cesarean delivery, gestational diabetes, or diabetes during…

FDA approves bimekizumab, now Bimzelx, for active AS and nr-axSpA

The U.S. Food and Drug Administration (FDA) has approved Bimzelx (bimekizumab-bkzx) for adults with active ankylosing spondylitis (AS), UCB Biopharm, the therapy’s developer, has announced. The dual interleukin-17A (IL-17A)/IL-17F inhibitor’s approval also extends to adults with active nonradiographic axial spondyloarthritis (nr-axSpA) with signs of inflammation and active psoriatic…

Two cell-death genes linked to disease development in AS

Changes in the activity of two genes related to a type of programmed cell death called necroptosis — also implicated in other autoimmune diseases — were linked to the development of ankylosing spondylitis (AS), a new study revealed. Those genes, FASLG and TARDBP, were “pinpointed” with the aid of three machine learning…

Potential sex-specific AS genetic markers seen, may aid treatment

Genetic analyses found altered activity in several genes related to programmed cell death in ankylosing spondylitis (AS) patients that was not evident in healthy individuals, a study reported. Significantly distinct genetic differences between men and women with AS also were identified, which researchers suggest may serve as new sex-specific…

NSAID dosing tied to increased risk of cardiovascular disease in AS

Treatment with high doses of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of cardiovascular disease among adults with ankylosing spondylitis (AS), according to a Korean real-world study into NSAID dosing. Specifically, the risk was significantly higher for conditions such as heart attack, stroke, and congestive heart…

axSpA patients stayed longest on TNF inhibitor golimumab: Study

Adults with axial spondyloarthritis (axSpA) remained on golimumab longer than any other TNF inhibitor, according to a real-world analysis of medical records. Although adalimumab (marketed as Humira and biosimilars) was the most commonly prescribed first- and second-line TNF inhibitor, patients stayed with golimumab (marketed…